Two 510(k) records in the supplied collection name VPIX Medical, Inc. as applicant, both decided Substantially Equivalent and both listing Daejeon, Republic of Korea, as the applicant address. K254030 covers cCeLL405, received 2025-12-16 and decided 2026-10-02. K260315 covers cCeLL - In vivo, received 2026-01-30 and decided 2026-10-16. The collection holds two linked records, both under the 510(k) pathway, and both carry a Substantially Equivalent decision; the record sample is the same two entries. These counts describe the supplied filings as of the snapshot and are not measures of total portfolio, sales or safety performance. [1][2][3]
Documented clearances and their scope
K260315 lists cCeLL - In vivo under product code GWG, regulation 21 CFR 882.1480, device class 2, with Neurology as the advisory committee and Traditional clearance type. The FDA database page for the same submission records the 01/30/2026 receipt and 10/16/2026 decision, Substantially Equivalent, not reviewed by a third party. K254030 lists cCeLL405 under product code QFX, regulation 21 CFR 882.4950, device class 2, also Traditional and Neurology. [1][2][3]
A separate clearance letter in the sources addresses K233391, dated August 21, 2024, for trade name cCeLL - In vivo under 21 CFR 882.1480, Neurological Endoscope, Class II, product codes GWG and OWN. Its stated indication concerns visualization of vessels and blood flow in the cerebrovasculature before, during or after cranial diagnostic and therapeutic procedures such as tumor biopsy and resection. That letter is not one of the two portfolio records. [4]
A February 13, 2026 letter covers K251852 for cCeLL - In vivo with Drop-In Robo, identified by model numbers CN100-2W2C488775, CN100-1W1C775 and DR200, under 21 CFR 876.1500, Endoscope And Accessories, Class II, product codes OWN and GCJ. The letter states that, based on non-clinical performance testing results, the device is substantially equivalent to the legally marketed predicate device and does not raise new concerns of safety and effectiveness. [6]
Product descriptions from company pages
VPIX Medical's English product page describes cCeLL - Ex vivo as an in vitro diagnostics medical device that provides physicians digital images of tissue at a microscopic level in real time. It names Pixection - Pen as a hand-held probe that contacts tissue after the patient's tissue is stained and generates a digital image. The Korean-language product page gives a comparable description, stating that the probe scans tissue with a laser and converts scanned optical signals into an image. [5][7]
The company homepage presents a digital biopsy platform for intraoperative consultation during cancer surgery and lists clinical image categories for brain, breast, lung, stomach, pancreas, large intestine, kidney and prostate. A company news item dated 2026-08-19 states that papers on cCeLL's clinical performance were published in international journals. These are company-published statements; the public documents contain no independent efficacy data or clinical outcome figures. [8][9]
A company news item dated 2024-10-02 describes FDA 510(k) clearance of cCeLL - In vivo and attributes the device to miniature confocal microscopy technology for visualizing brain tumors and microstructures in real time. The same item calls the clearance a second FDA approval. The public documents do not establish corporate ownership, parent entities, headquarters, customers or commercial availability. [10]
Reading the filing record
The two portfolio entries and the additional letters describe related but distinct device configurations: cCeLL405, cCeLL - In vivo, cCeLL - In vivo with Drop-In Robo, and the ex vivo platform with its Pixection - Pen probe. Product codes differ across them, GWG for K260315, QFX for K254030, and GWG with OWN for K233391, so the records should not be treated as one clearance. The public documents do not state shipment status, pricing or post-market data for any configuration. [1][2][4][5]
